Angiotensin II receptor blockers in older patients

Area of Science:

• Cardiology
• Geriatrics
• Pharmacology

Background:

• Older hypertensive patients are often undertreated due to misconceptions about blood pressure goals and side effects.
• Effective hypertension management significantly improves morbidity and quality of life across all age groups.
• Renin-angiotensin-aldosterone system antagonists are particularly beneficial for elderly individuals with comorbidities like diabetes and renal dysfunction.

Purpose of the Study:

• To review the efficacy and safety of angiotensin II receptor blockers (ARBs) in older hypertensive patients.
• To highlight the benefits of ARBs in managing hypertension-related complications such as left ventricular hypertrophy and renal disease.
• To discuss the role of ARBs in treating heart failure and post-myocardial infarction patients, especially those intolerant to ACE inhibitors.

Main Methods:

• Review of key clinical trials including LIFE, Val-HeFT, CHARM, and VALIANT.
• Analysis of evidence supporting the use of ARBs in elderly populations.
• Evaluation of ARBs for specific cardiovascular conditions and patient profiles.

Main Results:

• ARBs demonstrate effectiveness in treating hypertension in older patients.
• Treatment with ARBs improves complications like left ventricular hypertrophy and renal disease.
• ARBs are suitable for heart failure and post-myocardial infarction patients, including those unable to tolerate ACE inhibitors.

Conclusions:

• Angiotensin II receptor blockers are a well-suited therapeutic option for hypertension in the elderly.
• ARBs offer significant benefits for cardiovascular health in older adults with hypertension and related conditions.
• Evidence supports the use of ARBs in heart failure and acute myocardial infarction management, providing an alternative for ACE inhibitor-intolerant patients.